Human Papillomavirus (HPV) Drug Pipeline Analysis Report 2025
Description
According to the HPV Information Centre, the global prevalence of Human Papillomavirus (HPV) infection in women is approximately 11-12%. The highest prevalence is in regions like sub-Saharan Africa (24%), Eastern Europe (21%) and Latin America (16%). Common medications given to manage the disease include salicylic acid, imiquimod, and trichloroacetic acid among others. Several clinical trials are ongoing to develop innovative human papillomavirus (HPV) therapies to improve and manage the condition including vaccines.
Report Coverage
The Human Papillomavirus (HPV) Pipeline Report by Expert Market Research gives comprehensive insights into human papillomavirus (HPV) therapeutic products currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Human Papillomavirus (HPV). The human papillomavirus (HPV) pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Human Papillomavirus (HPV).
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing human papillomavirus (HPV) development activities related to Human Papillomavirus (HPV) are covered.
Human Papillomavirus (HPV) Drug Pipeline Outlook
Human papillomavirus is a viral infection which commonly causes skin or mucous membrane growths. There are several varieties of human papillomavirus. Some types of infection cause warts and some cause different types of cancer. Generally, human papillomavirus infections don't lead to cancer, but some are linked to causing uterine cancer. Other cancers linked to human papillomavirus infection include anus, vagina, penis, vulva and back of the throat. The symptoms depend on the type of human papillomavirus type, which includes genital warts, common warts, plantar warts, and flat warts.
The medications for human papillomavirus infection are used to eliminate warts and are applied directly to the lesion. It includes salicylic acid, imiquimod, podofilox, trichloroacetic acid. Over-the-counter treatments include salicylic acids which work by removing layers of a wart. On the other hand, Imiquimod is a prescription cream and it is used to enhance the immune system's ability to fight human papillomavirus infection. Podofilox is another topical prescription which works by destroying genital wart tissue and trichloroacetic acid is a chemical treatment which burns off warts on the soles, palms, and genitals. Clinical trials for human papillomavirus therapeutics are focusing on several aspects. Merck announced the clinical development of a new investigational multi-valent human papillomavirus vaccine. It is designed to provide broader protection against multiple types of human papillomavirus. Additionally, Merck also plans to conduct clinical trials to assess the safety of a single-dose regimen of GARDASIL®9 in both males and females. The increased number of drugs clinical trials for human papillomavirus has impacted the human papillomavirus (HPV) pipeline landscape significantly.
Human Papillomavirus (HPV) – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of human papillomavirus (HPV) emerging drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s human papillomavirus (HPV) therapeutic assessment covers 50+ drug analyses based on drug classes:
EMR’s human papillomavirus (HPV) clinical assessment covers 50+ drug analyses based on the route of administration.
The human papillomavirus (HPV) report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases . According to EMR analysis , phase II covers a major share of the total clinical trials for human papillomavirus.
Human Papillomavirus (HPV) – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under the human papillomavirus (HPV) pipeline analysis include small molecule, gene therapy, cell therapy, and immunotherapy. Several studies are investigating T-cell therapies for the treatment of metastatic human papillomavirus infection-associated epithelial cancers. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for human papillomavirus (HPV).
Human Papillomavirus (HPV) Clinical Trials Assessment – Competitive Dynamics
The EMR human papillomavirus (HPV) report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Human Papillomavirus (HPV) clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and human papillomavirus (HPV) therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming human papillomavirus (HPV) drug candidates.
Biological: Cervarix
The trial is designed to evaluate the immunogenicity of GSK Biologicals' HPV-16/18 L1 AS04 vaccine in female patients who are enrolled from multiple countries in Africa. The trial is sponsored by GlaxoSmithKline and is currently under phase III.
Biological: VGX-3100
The objective of the study is to evaluate the safety of human papillomavirus DNA Plasmid (VGX-3100) in adult females previously immunized with VGX-3100. The trial is sponsored by Inovio Pharmaceuticals and is currently under phase I.
Biological: V503
Merck Sharp & Dohme LLC is developing this human papillomavirus (HPV) drug candidate and is currently under phase III. The study is being conducted to evaluate the efficacy of a multivalent human papillomavirus L1 Virus-Like Particle (VLP) Vaccine. It is being administered to preadolescents and adolescents.
Reasons To Buy This Report
The Human Papillomavirus (HPV) Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for human papillomavirus (HPV). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within human papillomavirus (HPV) pipeline insights.
Key Questions Answered in the Human Papillomavirus (HPV) – Pipeline Assessment Report
Global Human Papillomavirus (HPV) Vaccine Market
Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market
Report Coverage
The Human Papillomavirus (HPV) Pipeline Report by Expert Market Research gives comprehensive insights into human papillomavirus (HPV) therapeutic products currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Human Papillomavirus (HPV). The human papillomavirus (HPV) pipeline insight includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Human Papillomavirus (HPV).
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing human papillomavirus (HPV) development activities related to Human Papillomavirus (HPV) are covered.
Human Papillomavirus (HPV) Drug Pipeline Outlook
Human papillomavirus is a viral infection which commonly causes skin or mucous membrane growths. There are several varieties of human papillomavirus. Some types of infection cause warts and some cause different types of cancer. Generally, human papillomavirus infections don't lead to cancer, but some are linked to causing uterine cancer. Other cancers linked to human papillomavirus infection include anus, vagina, penis, vulva and back of the throat. The symptoms depend on the type of human papillomavirus type, which includes genital warts, common warts, plantar warts, and flat warts.
The medications for human papillomavirus infection are used to eliminate warts and are applied directly to the lesion. It includes salicylic acid, imiquimod, podofilox, trichloroacetic acid. Over-the-counter treatments include salicylic acids which work by removing layers of a wart. On the other hand, Imiquimod is a prescription cream and it is used to enhance the immune system's ability to fight human papillomavirus infection. Podofilox is another topical prescription which works by destroying genital wart tissue and trichloroacetic acid is a chemical treatment which burns off warts on the soles, palms, and genitals. Clinical trials for human papillomavirus therapeutics are focusing on several aspects. Merck announced the clinical development of a new investigational multi-valent human papillomavirus vaccine. It is designed to provide broader protection against multiple types of human papillomavirus. Additionally, Merck also plans to conduct clinical trials to assess the safety of a single-dose regimen of GARDASIL®9 in both males and females. The increased number of drugs clinical trials for human papillomavirus has impacted the human papillomavirus (HPV) pipeline landscape significantly.
Human Papillomavirus (HPV) – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of human papillomavirus (HPV) emerging drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s human papillomavirus (HPV) therapeutic assessment covers 50+ drug analyses based on drug classes:
- Small Molecule
- Gene Therapy
- Cell Therapy
- Immunotherapy
EMR’s human papillomavirus (HPV) clinical assessment covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The human papillomavirus (HPV) report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases . According to EMR analysis , phase II covers a major share of the total clinical trials for human papillomavirus.
Human Papillomavirus (HPV) – Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under the human papillomavirus (HPV) pipeline analysis include small molecule, gene therapy, cell therapy, and immunotherapy. Several studies are investigating T-cell therapies for the treatment of metastatic human papillomavirus infection-associated epithelial cancers. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for human papillomavirus (HPV).
Human Papillomavirus (HPV) Clinical Trials Assessment – Competitive Dynamics
The EMR human papillomavirus (HPV) report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Human Papillomavirus (HPV) clinical trials:
- Klein Buendel, Inc.
- Inovio Pharmaceuticals
- GlaxoSmithKline
- Genexine, Inc.
- Antiva Biosciences
- Xiamen Innovax Biotech Co., Ltd
- PT Bio Farma
- Wuhan BravoVax Co., Ltd.
- Shanghai Zerun Biotechnology Co., Ltd
- Hologic Deutschland GmbH
- Merck Sharp & Dohme LLC
- Gen-Probe, Incorporated
- Hoffmann-La Roche
- 2A Pharma AB
- Inovio Pharmaceuticals
- Others
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and human papillomavirus (HPV) therapeutic drugs. It covers necessary details such as product description, study type, drug class, mode of administration, and recruitment status of upcoming human papillomavirus (HPV) drug candidates.
Biological: Cervarix
The trial is designed to evaluate the immunogenicity of GSK Biologicals' HPV-16/18 L1 AS04 vaccine in female patients who are enrolled from multiple countries in Africa. The trial is sponsored by GlaxoSmithKline and is currently under phase III.
Biological: VGX-3100
The objective of the study is to evaluate the safety of human papillomavirus DNA Plasmid (VGX-3100) in adult females previously immunized with VGX-3100. The trial is sponsored by Inovio Pharmaceuticals and is currently under phase I.
Biological: V503
Merck Sharp & Dohme LLC is developing this human papillomavirus (HPV) drug candidate and is currently under phase III. The study is being conducted to evaluate the efficacy of a multivalent human papillomavirus L1 Virus-Like Particle (VLP) Vaccine. It is being administered to preadolescents and adolescents.
Reasons To Buy This Report
The Human Papillomavirus (HPV) Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for human papillomavirus (HPV). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within human papillomavirus (HPV) pipeline insights.
Key Questions Answered in the Human Papillomavirus (HPV) – Pipeline Assessment Report
- What is the current landscape of human papillomavirus (HPV) pipeline drugs?
- Which companies/institutions are developing human papillomavirus (HPV) emerging drugs?
- How many phase II drugs are currently present in human papillomavirus (HPV) pipeline drugs?
- Which company is leading the human papillomavirus (HPV) pipeline development activities?
- What is the current human papillomavirus (HPV) therapeutic assessment?
- What are the opportunities and challenges present in the human papillomavirus (HPV) drug pipeline landscape?
- What is the efficacy and safety profile of human papillomavirus (HPV) pipeline drugs?
- Which companies/institutions are involved in human papillomavirus (HPV) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in human papillomavirus (HPV)?
Global Human Papillomavirus (HPV) Vaccine Market
Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Human Papillomavirus (HPV)
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Human Papillomavirus (HPV)
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Human Papillomavirus (HPV): Epidemiology Snapshot
- 5.1 Human Papillomavirus (HPV) Incidence by Key Markets
- 5.2 Human Papillomavirus (HPV)– Patients Seeking Treatment in Key Markets
- 6 Human Papillomavirus (HPV): Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Human Papillomavirus (HPV): Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Human Papillomavirus (HPV), Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Human Papillomavirus (HPV) Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Human Papillomavirus (HPV) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Gardasil 9
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Cervarix
- 10.2.3 Biological: V503
- 10.2.4 Other Drugs
- 11 Human Papillomavirus (HPV) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: ABI-2280
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Biological: ProCervix
- 11.2.3 Other Drugs
- 12 Human Papillomavirus (HPV) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: ABI-2280
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Drug: TGN-S11
- 12.2.3 Other Drugs
- 13 Human Papillomavirus (HPV) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug: HB-201 IV
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Human Papillomavirus (HPV), Key Drug Pipeline Companies
- 14.1 Klein Buendel, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Inovio Pharmaceuticals
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 GlaxoSmithKline
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Genexine, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Antiva Biosciences
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Xiamen Innovax Biotech Co., Ltd
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 PT Bio Farma
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Wuhan BravoVax Co., Ltd.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Shanghai Zerun Biotechnology Co., Ltd
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Hologic Deutschland GmbH
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 14.11 Merck Sharp & Dohme LLC
- 14.11.1 Company Snapshot
- 14.11.2 Pipeline Product Portfolio
- 14.11.3 Financial Analysis
- 14.11.4 Recent News and Developments
- 14.12 Gen-Probe, Incorporated
- 14.12.1 Company Snapshot
- 14.12.2 Pipeline Product Portfolio
- 14.12.3 Financial Analysis
- 14.12.4 Recent News and Developments
- 14.13 Hoffmann-La Roche
- 14.13.1 Company Snapshot
- 14.13.2 Pipeline Product Portfolio
- 14.13.3 Financial Analysis
- 14.13.4 Recent News and Developments
- 14.14 2A Pharma AB
- 14.14.1 Company Snapshot
- 14.14.2 Pipeline Product Portfolio
- 14.14.3 Financial Analysis
- 14.14.4 Recent News and Developments
- 14.15 Inovio Pharmaceuticals
- 14.15.1 Company Snapshot
- 14.15.2 Pipeline Product Portfolio
- 14.15.3 Financial Analysis
- 14.15.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
